Additionally, the observed anti-obesity and hepatic lipid metabolism improvement effects following HMPA administration were evident only in wild-type mice, not in Gpr41−/− mice, indicating that HMPA acts as a molecular entity through GPR41. The gene discussed is FFAR3; the disease is obesity disorder.